Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer

Chinese Journal of Oncology

Volumn 33, Issue 3, 2011, Pages 212-216

  Zhang, Li ^a   Liu, Ting ^b   Zhang, Jian Qing ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Carcinoma, non small cell lung; Drug therapy; Prognosis; Treatment outcome; Tumor markers, biological

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; K RAS PROTEIN; PLATINUM DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RAS PROTEINS; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS; TUBULIN; VINBLASTINE;

EID: 80052697473     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.03.013     Document Type: Article

References (12)

1. Coate LE, John T, Tsao MS, et al. Molecular predictive and prognostic markeis in non-small-cell lung cancer. Lancet Oncol, 2009, 10: 1001-1010.
2. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Nol Cancer, 2008, 7:81.
3. Hwang IG, Ahn MJ, Park BB, et al. ERCC1 expression as a prognostic marker in N2(+) non-small-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer, 2008, 113:1379-1386.
4. Panasci LC. Different impact of excision repair cross-complementing group 1 on survival. J Clin Oncol, 2010, 28:e163.
5. Kim HT, Lee JE, Shin ES, et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol, 2008, 26:5972-5979.
6. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One, 2009, 4:e5133.
7. Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol, 2008, 9: 168-175. (Pubitemid 351150128)
8. Hayashi Y, Kuriyama H, Umezu H, et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med, 2009, 48:203-208.
9. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic K-ras mutations as a mechanism associated with resistance to EGFR-targeted agents; a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol, 2008, 9:962-972.
10. Riely GJ, Kris MG, Rosenbaum D, et, al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res, 2008, 14:5731-5734.